Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.58 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | CHUK | O15111 | 1/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 3/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21246919 | 0.86 | PTPRC (0.51) | RAB9AL3MBTL1ALDH1A1FFAR2XDH | |
| SCHEMBL6281119 | 0.85 | MAPK8 (0.50) | MAPK8CAMKK2FYNCHUKINSR | |
| SCHEMBL12189290 | 0.84 | L3MBTL1 (0.60) | SMN1; SMN2L3MBTL1ALDH1A1FFAR2XDH | |
| SCHEMBL1222758 | 0.84 | RXRA (0.58) | PDE4APDE4BPDE4CPDE4DCA1 | |
| SCHEMBL2039480 | 0.83 | FFAR2 (0.49) | L3MBTL1FFAR2XDHPTPRCPTPN1 | |
| SCHEMBL2050621 | 0.83 | EGFR (0.56) | RAB9ASMN1; SMN2L3MBTL1CA1CA2 | |
| SCHEMBL29788043 | 0.83 | EGFR (0.56) | RAB9ASMN1; SMN2L3MBTL1CA1CA2 | |
| SCHEMBL27847027 | 0.83 | ATM (0.56) | RAB9AL3MBTL1ALDH1A1FFAR2XDH | |
| SCHEMBL27615625 | 0.83 | MKNK1 (0.49) | MAPK8CAMKK2FYNCHUKINSR | |
| SCHEMBL3861503 | 0.82 | KAT6A (0.56) | FYNPDE4DPARP1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544808-B2 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-09 | — | — | US | claimed |
| EP-1703797-A4 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | claimed |
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | claimed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| EP-1534273-A4 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-08-22 | — | — | EP | claimed |
| US-7253283-B2 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | claimed |
| EP-1703797-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-09-27 | — | — | EP | claimed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-6995181-B2 | Modulators of the glucocorticoid receptor and method | BRISTOL-MYERS SQUIBB CO. (US) | 2006-02-07 | — | — | US | claimed |
| US-20050187242-A1 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | claimed |
| WO-2005072132-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050171136-A1 | Modulators of the glucocorticoid receptor and method | VACCARO WAYNE (US) | 2005-08-04 | — | — | US | claimed |
| EP-1534273-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | Bristol-Myers Squibb Company (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | claimed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | claimed |
| EP-3466934-B1 | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-11634395-B2 | Sulfonamide compound or salt thereof | Taiho Pharmaceutial Co., Ltd. (JP) | 2023-04-25 | — | — | US | disclosed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1263755-A2 | CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001070673-A2 | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKBIA, NFKB1 | MAPK8 437/4885CAMKK2 604/4885FYN 3711/4885 |
| US-20050187242-A1 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKBIA, NFKB1 | MAPK8 437/4885CAMKK2 604/4885FYN 3711/4885 |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | NR3C1, NR3C2, MC2R | MAPK8 2495/4885CAMKK2 2228/4885FYN 3398/4885 |
| US-20050171136-A1 | Modulators of the glucocorticoid receptor and method | NR3C1, MC2R, NR3C2 | MAPK8 2256/4885CAMKK2 1917/4885FYN 3223/4885 |
| US-11634395-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | MAPK8 2438/4885CAMKK2 4782/4885FYN 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.